Published in Curr Med Chem on January 01, 2006
Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol (2010) 2.00
New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol (2014) 1.53
Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol (2010) 1.38
Zebrafish lipid metabolism: from mediating early patterning to the metabolism of dietary fat and cholesterol. Methods Cell Biol (2011) 1.03
A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development. Nutr Metab (Lond) (2008) 0.95
Natural compounds as regulators of the cancer cell metabolism. Int J Cell Biol (2013) 0.91
Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: a comparative glucose tracer study with the fatty acid synthase inhibitor C75. Metabolomics (2011) 0.90
The importance of NAD in multiple sclerosis. Curr Pharm Des (2009) 0.89
Enhancing the health-promoting effects of tomato fruit for biofortified food. Mediators Inflamm (2014) 0.89
Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine. Evid Based Complement Alternat Med (2014) 0.86
A new model system swims into focus: using the zebrafish to visualize intestinal metabolism in vivo. Clin Lipidol (2009) 0.85
Signal transduction and molecular targets of selected flavonoids. Antioxid Redox Signal (2013) 0.83
The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors. Curr Pharm Biotechnol (2013) 0.77
Inhibition of Rat 5α-Reductase Activity and Testosterone-Induced Sebum Synthesis in Hamster Sebocytes by an Extract of Quercus acutissima Cortex. Evid Based Complement Alternat Med (2015) 0.77
Morin, a novel LXRα/β dual antagonist, has potent therapeutic efficacy for nonalcoholic fatty liver diseases. Br J Pharmacol (2017) 0.75